Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F12%3A%230002064" target="_blank" >RIV/00023728:_____/12:#0002064 - isvavai.cz</a>
Result on the web
<a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1112072" target="_blank" >http://www.nejm.org/doi/full/10.1056/NEJMoa1112072</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1112072" target="_blank" >10.1056/NEJMoa1112072</a>
Alternative languages
Result language
angličtina
Original language name
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Original language description
In the article are presented results of the study with tofacitinib or adalimumab compare to placebo in the metotrexate-failure patients with rheumatoid arthritis.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
NEW ENGLAND JOURNAL OF MEDICINE
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
367
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
508-519
UT code for WoS article
000307310800005
EID of the result in the Scopus database
—